1Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation [J].Adv Drug Deliv Rev, 2002, 54(4) : 459- 476.
2Kim SH, Jeong JH, Lee SH, et al. PEG conjugated VEGF siR NA for anti-angiogenic gene therapy [J]. J Control Release, 2006, 116(2): 123-129.
3Talpaz M, Rakhit A, Rittweger K, et al. Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without eytarabine in patients with chronic myelogenous leukemia [J]. Clin Cancer Res, 2005, 11(17): 6247-6255.
4Leach JK, Hinman A, O'Rear EA. Investigation of deformability, viscosity, and aggregation of mPEG-modified erythrocytes[J]. Biomed Sci Instrum, 2002, 38: 333-338.
5Bradley AJ, Test ST, Murad KL, et al. Interactions of IgM ABO antibodies and complement with methoxy-PEG-modified human RBCs[[J]. Transfusion, 2001, 41(10): 1 225-1 233.
6Tan Y, Qiu Y, Xu H, et al. Decreased immunorejection in un matched blood transfusions by attachment of methoxypolyethylene glycol on human red blood cells and the effect on D antigen[J]. Transfusion, 2006, 46(12): 2 122-2 127.
7Bradley AJ, Murad KL, Regan KL, et al. Biophysical consequences of linker chemistry and polymer size on stealth erythrocytes: size does matter[J]. Biochim Biophys Acta, 2002,1 561 (2) : 147-158.
8Doucet J, Gao ZH, MacLaren LA, et al. Modification of xenoantigens on porcine erythrocytes for xenotransfusion [J]. Surgery, 2004, 135(2): 178-186.
9Gundersen SI, Palmer AF. Conjugation of methoxypolyethylene glycol to the surface of bovine red blood cells[J]. Biotechnol Bioeng, 2007, 96(6): 1 199-1 210.
10Scott MD, Chen AM. Beyond the red cell: pegylation of other blood cells and tissues [J]. Transfus Clin Biol, 2004, 11(1) : 40- 46.
